Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
2.86% $3.96
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 123.19 mill |
EPS: | -1.710 |
P/E: | -2.32 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 31.11 mill |
Avg Daily Volume: | 0.855 mill |
RATING 2024-03-28 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | n/a | |||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.32 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.39x |
Company: PE -2.32 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.760 (-55.54%) $-2.20 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 3.54 - 4.38 ( +/- 10.66%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Shepard Kirk V. | Buy | 200 000 | Employee Stock Option (Right to Buy) |
2024-01-22 | Shepard Kirk V. | Buy | 0 | |
2023-12-04 | Boesgaard Lars | Buy | 200 000 | Employee Stock Option (Right to Buy) |
2023-12-04 | Boesgaard Lars | Buy | 0 | |
2023-07-14 | Freitag Gregory Gene | Buy | 9 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
70.77 |
Last 91 transactions |
Buy: 4 791 106 | Sell: 920 084 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.96 (2.86% ) |
Volume | 2.27 mill |
Avg. Vol. | 0.855 mill |
% of Avg. Vol | 266.04 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.31 | N/A | Active |
---|
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.